Literature DB >> 32516866

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis.

Hiromichi Shimizu1, Toshimitsu Fujii1, Shuji Hibiya1, Maiko Motobayashi2, Kohei Suzuki3, Kento Takenaka2, Eiko Saito1, Masakazu Nagahori1, Kazuo Ohtsuka2, Mamoru Watanabe4.   

Abstract

Entities:  

Year:  2020        PMID： 32516866     DOI： 10.5217/ir.2020.00030

Source DB:  PubMed          Journal:  Intest Res        ISSN： 1598-9100


× No keyword cloud information.
  4 in total

1.  Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis.

Authors:  Laura A Lucaciu; Nathan Constantine-Cooke; Nikolas Plevris; Spyros Siakavellas; Lauranne A A P Derikx; Gareth-Rhys Jones; Charles W Lees
Journal:  Therap Adv Gastroenterol       Date:  2021-12-23       Impact factor: 4.409

2.  Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis.

Authors:  Masanao Nakamura; Takeshi Yamamura; Keiko Maeda; Tsunaki Sawada; Yasuyuki Mizutani; Eri Ishikawa; Takuya Ishikawa; Naomi Kakushima; Kazuhiro Furukawa; Eizaburo Ohno; Hiroki Kawashima; Takashi Honda; Masatoshi Ishigami; Mitsuhiro Fujishiro
Journal:  Nagoya J Med Sci       Date:  2022-02       Impact factor: 1.131

Review 3.  Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.

Authors:  Soo-Young Na; You Sun Kim
Journal:  Korean J Intern Med       Date:  2022-08-10       Impact factor: 3.165

Review 4.  Review article: guide to tofacitinib dosing in patients with ulcerative colitis.

Authors:  Peter M Irving; Yvette Leung; Marla C Dubinsky
Journal:  Aliment Pharmacol Ther       Date:  2022-08-22       Impact factor: 9.524
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.